Tiziana(NASDAQ:TLSA) said the study demonstrated that nasal administration of foralumab, an anti-CD3 monoclonal antibody, significantly reduced neuroinflammation and improved recovery. The study ...

Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 10 patients with Non ...

A recent groundbreaking study published in Nature has opened a promising new chapter in the treatment of traumatic brain ...

Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 10 patients with Non ...

Nasal anti-CD3 monoclonal antibody ameliorates traumatic brain injury, enhances microglial phagocytosis and reduces neuroinflammation via IL-10-dependent Treg–microglia crosstalk ...

anti-CD3 monoclonal antibody, today announced that the CEO of Tiziana Life Sciences, Ivor Elrifi, will be presenting during a fireside chat at the 37th Annual ROTH Conference and host 1x1 investor ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

Tiziana was previously notified by Nasdaq on January 29, 2025 that it was not in compliance with the minimum bid-price listing rule (under Rule 5550 (a) (2)) because its common stock failed to meet ...

Reference: Izzy S, Yahya T, Albastaki O, et al. Nasal anti-CD3 monoclonal antibody ameliorates traumatic brain injury, enhances microglial phagocytosis and reduces neuroinflammation via ...